Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter
Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/19/5959 |
| _version_ | 1797478468009590784 |
|---|---|
| author | Anca Trifan Remus Stafie Adrian Rotaru Ermina Stratina Sebastian Zenovia Robert Nastasa Laura Huiban Tudor Cuciureanu Cristina Muzica Stefan Chiriac Irina Girleanu Ana-Maria Singeap Catalin Sfarti Camelia Cojocariu Oana Petrea Carol Stanciu |
| author_facet | Anca Trifan Remus Stafie Adrian Rotaru Ermina Stratina Sebastian Zenovia Robert Nastasa Laura Huiban Tudor Cuciureanu Cristina Muzica Stefan Chiriac Irina Girleanu Ana-Maria Singeap Catalin Sfarti Camelia Cojocariu Oana Petrea Carol Stanciu |
| author_sort | Anca Trifan |
| collection | DOAJ |
| description | Background and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (<i>β</i> = 0.357, <i>p</i> = 0.021), body mass index (BMI) (<i>β</i> = 0.185, <i>p</i> = 0.048), disease duration (<i>β</i> = 0.297, <i>p</i> = 0.041), C—reactive protein (<i>β</i> = 0.321, <i>p</i> = 0.013), fasting plasma glucose (<i>β</i> = 0.269, <i>p</i> = 0.038), and triglycerides (<i>β</i> = 0.273, <i>p</i> = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies. |
| first_indexed | 2024-03-09T21:32:18Z |
| format | Article |
| id | doaj.art-4ac34a1e5fa64435b228b166d5b95b15 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:32:18Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-4ac34a1e5fa64435b228b166d5b95b152023-11-23T20:51:41ZengMDPI AGJournal of Clinical Medicine2077-03832022-10-011119595910.3390/jcm11195959Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation ParameterAnca Trifan0Remus Stafie1Adrian Rotaru2Ermina Stratina3Sebastian Zenovia4Robert Nastasa5Laura Huiban6Tudor Cuciureanu7Cristina Muzica8Stefan Chiriac9Irina Girleanu10Ana-Maria Singeap11Catalin Sfarti12Camelia Cojocariu13Oana Petrea14Carol Stanciu15Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaDepartment of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 70015 Iasi, RomaniaBackground and Aims: Inflammatory bowel diseases (IBD) are frequently associated with extraintestinal manifestations, hepatic injury being of concern in these patients. Current literature reports an increased prevalence of liver steatosis and fibrosis in subjects with IBD and the pathophysiology is yet to be completely understood. The aim of this study was to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with IBD, as well as to determine the factors that connect these two disorders. Methods: From September 2021 to June 2022, 82 consecutive IBD patients were enrolled from a tertiary care center hospital in Iasi. Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter (CAP) was used to assess the presence of NAFLD, with a cut-off score for CAP of 248 dB/m. Significant liver fibrosis was considered at a cut-off for liver stiffness measurements (LSM) of 7.2 kPa. Results: In total, 82 IBD patients (54.8% men, mean age of 49 ± 13 years) were included, 38 (46.3%) of them being diagnosed with NAFLD, with a mean CAP score of 286 ± 35.4 vs. 203 ± 29.7 in patients with IBD only. Age (<i>β</i> = 0.357, <i>p</i> = 0.021), body mass index (BMI) (<i>β</i> = 0.185, <i>p</i> = 0.048), disease duration (<i>β</i> = 0.297, <i>p</i> = 0.041), C—reactive protein (<i>β</i> = 0.321, <i>p</i> = 0.013), fasting plasma glucose (<i>β</i> = 0.269, <i>p</i> = 0.038), and triglycerides (<i>β</i> = 0.273, <i>p</i> = 0.023) were strongly associated with the presence of liver steatosis. The multivariate analysis showed that older age, BMI, and disease duration were strongly associated with significant liver fibrosis in our group. Conclusions: NAFLD is a multifaced pathology with growing prevalence among IBD patients. Additional studies are needed to completely understand this problem and to create a solid evidence-based framework for more effective preventative and intervention strategies.https://www.mdpi.com/2077-0383/11/19/5959inflammatory bowel diseasenon-alcoholic fatty liver diseaseliver fibrosisvibration-controlled transient elastography |
| spellingShingle | Anca Trifan Remus Stafie Adrian Rotaru Ermina Stratina Sebastian Zenovia Robert Nastasa Laura Huiban Tudor Cuciureanu Cristina Muzica Stefan Chiriac Irina Girleanu Ana-Maria Singeap Catalin Sfarti Camelia Cojocariu Oana Petrea Carol Stanciu Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter Journal of Clinical Medicine inflammatory bowel disease non-alcoholic fatty liver disease liver fibrosis vibration-controlled transient elastography |
| title | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
| title_full | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
| title_fullStr | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
| title_full_unstemmed | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
| title_short | Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter |
| title_sort | screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter |
| topic | inflammatory bowel disease non-alcoholic fatty liver disease liver fibrosis vibration-controlled transient elastography |
| url | https://www.mdpi.com/2077-0383/11/19/5959 |
| work_keys_str_mv | AT ancatrifan screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT remusstafie screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT adrianrotaru screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT erminastratina screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT sebastianzenovia screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT robertnastasa screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT laurahuiban screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT tudorcuciureanu screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT cristinamuzica screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT stefanchiriac screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT irinagirleanu screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT anamariasingeap screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT catalinsfarti screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT cameliacojocariu screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT oanapetrea screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter AT carolstanciu screeningforliversteatosisandfibrosisinpatientswithinflammatoryboweldiseaseusingvibrationcontrolledtransientelastographywithcontrolledattenuationparameter |